The global CAR T cell market is growing continuously due to innovation and development in this therapy. It is estimated, the Global CAR T cell therapy market size will exhibit a remarkable CAGR of 52% from 2019 to 2025.
As per the National Cancer Institute, Chimeric Antigen Receptor (CAR) T cell therapy is one type of treatment for cancer, which helps to change patients T cells so they will attack cancer cells. Firstly the CAR T cell ingrown in the laboratory, and it was given to patients by infusion. The distinctive characteristic of CAR T cell is to bind to an antigen on the cancer cells and kill them. CAR T cells therapy treatment is mostly used in blood cancer and some among others. Recently, CAR T cell therapy has preferred over radiation and chemotherapy.
CAR T cell becomes activated when they are targeted over antigen and binds to it to destroy the specific cells. The transfer of T cells is an anti-cancer therapeutic process that focuses virtually by any tumour-associated antigen. In earlier days, these are only applicable for the blood cancers but later ion with the advanced technologies; these are moved to various types of cancers.
MARKET DRIVERS
Awareness regarding health and wellness, modification in various disorders, and government support across the world are vital factors that ramp up the CAR T cell therapy market coming years. Although, the t- cell treatment systems are available all oncology speciality hospitals and providing immediate therapy to patients in clinic and ambulatory centres which help to reach highest CAR T cell market in the world. T cell therapy has the fastest growth rate in lymphoma treatment because the patients have not preferred to another medication.
Additionally, the rise in chronic diseases like cancer across the world is a crucial driving factor for the market to grow extensively. The increased support from the government in introducing reimbursement schemes in favour of the poor people is also escalating the demand of the market. Also, the rapid development in industries and support across all regions is the new opportunity for CAR T cell therapy market.
Furthermore, the implementation of procedures with advanced technologies and also the introduction of innovative treatment procedures with fewer side effects are expected to surge the growth rate of the market. Rise in the investments on the research institutes related to cell therapy is another considerable factor supporting market growth.
MARKET RESTRAINTS
Lack of awareness in the rural areas towards the therapeutic process for cancer disease is slightly restraining the demand of the CAR T cell therapy market. The cost of this therapy is a bit expensive, which cannot be affordable by ordinary people is also hindering the demand of the market. An increasing adverse drug reaction concern with cell therapy in Cytokine syndrome problems and the neurological problem is expected to hamper the CAR T cell therapy market growth to some extent.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 to 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 to 2024 |
|
Segments Covered |
By Target Antigen, Application, Product, Therapies and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This research report on the global CAR T Cell therapy market segmented and sub-segmented based on target antigen, Application, Product, therapies and Region.
CAR T cell Therapy Market - By Target Antigen
Based on target antigen, segments like CD/19 & CD/22 had the largest share in the global market in 2019 and is expected to continue their dominance throughout the forecast period. In recently, several companies got their antigens approved it also increases the T cell therapy market. B-cell maturation antigens are anticipated to fastest growth due to its distinctive antigens such as MUC16, ROR1 and L1CAM.
CAR T cell Therapy Market - By Application
Based on Application, the Multiple Myeloma sector is leading with the highest shares of the market from the past decade and also estimated to continue the same growth in the coming years. Multiple myeloma segment has grown in T cell therapy market. The new acute lymphocytic leukaemia segment is expected to grow in coming decades. The Diffuse large B-cell lymphoma (DLBCL) segment is another lucrative segment and is standing next to in occupying second-best majority shares in the market.
CAR T cell Therapy Market - By Product
CAR T cell Therapy Market Analysis - By Therapies
CAR T cell Therapy Market – By End User
CAR T cell Therapy Market Analysis – By Region
Regionally, North America leads the global market. By owing to the quick adoption of advanced technologies and also rise in cancer, patients are fueling the demand of the market in this Region. North America region is continuously growing in CAR T cell market by owing to academic institutions, government authority, and several manufacturing industries. Also, the United States is the highest market in the adoption of CAR T cell therapy. Also, some industries got USFDA Approval for the development in CAR T cell therapy treatment.
Followed by North America, Asia pacific is holding the highest shares of the market with the increased research process on the blood cancer treatment process. Asia-pacific is the growing market due to China and India; it has several manufacturing industries and the number of cancer patients from that Region.
Europe region is the fastest-growing Region in CAR T cell market due to the recent approvals of Kymriah and Yescarta by European medicine agency; it will grow in CAR T cell market.
TOP COMPANIES IN THE MARKET
Companies playing a leading role in the global CAR T cell therapy market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.
RECENT MARKET DEVELOPMENTS
